Pacira Pharmaceuticals Stock News

A potential rival hopes to win FDA approval of a generic version of Pacira's top-selling pain drug.

TAMPA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has recei

Marks key step in achieving EXPAREL gross margins that exceed 85 percent by 2024 Marks key step in achieving EXPAREL gross margins that exceed 85 percent by 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmuneID appoints veteran biotech executive James S. Scibetta as Chief Executive Officer.

Study demonstrating safety and tolerability of EXPAREL published in Journal of Clinical Anesthesia Study demonstrating safety and tolerability of EXPAREL published in Journal of Clinical Anesthesia

You should want to know, because knowing when to put the gain in your wallet to be reinvested in the next one has very few better strategies.

-- Expanding EXPAREL utilization continues to drive growth with average daily sales at 109% of August 2020 -- -- More than nine million patients treated with EXPAREL as of August 2021 --

PARSIPPANY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:0

-- EXPAREL momentum continues with July 2021 average daily sales at 117% of July 2020 -- -- EXPAREL momentum continues with July 2021 average daily sales at 117% of July 2020 --

Pacira's (PCRX) earnings and revenues in the second quarter of 2021 surpass estimates. Exparel sales surge year over year.

Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q2 2021 Results - Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of 1.32% and -0.01%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

-- EXPAREL average daily sales at 178% of the prior year second quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nas

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PARSIPPANY, N.J., July 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets